{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:36:32Z","timestamp":1792892192127,"version":"4.5.0"},"reference-count":73,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2020,7,15]]},"abstract":"<jats:p>Immuno\u2010oncology therapies engage the immune system to treat cancer. BiTE (bispecific T\u2010cell engager) technology is a targeted immuno\u2010oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor\u2010specific antigens, allowing off\u2010the\u2010shelf immuno\u2010oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B\u2010cell non\u2010Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small\u2010cell lung cancer). BiTE molecules with an extended half\u2010life relative to the canonical BiTE molecules are also being developed. Advances in immuno\u2010oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.<\/jats:p>","DOI":"10.1002\/cncr.32909","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T14:51:13Z","timestamp":1589381473000},"page":"3192-3201","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["The BiTE (bispecific T\u2010cell engager) platform: Development and future potential of a targeted immuno\u2010oncology therapy across tumor types"],"prefix":"10.1002","volume":"126","author":[{"given":"Hermann","family":"Einsele","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II Universit\u00e4t W\u00fcrzburg W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":false,"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Fox Chase Cancer Center Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"Department of Medicine III University Hospital Ludwig\u2010Maximilians University Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine Division of Hematology and Oncology The New York Presbyterian Hospital New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kufer","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Iskander","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0623-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0453-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00315"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0422"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00609"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-567453"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02204"},{"key":"e_1_2_8_9_1","volume-title":"IMFINZI (durvalumab) [package insert]","year":"2017"},{"key":"e_1_2_8_10_1","volume-title":"KEYTRUDA (pembrolizumab) [package insert]","year":"2014"},{"key":"e_1_2_8_11_1","volume-title":"TECENTRIQ (atezolizumab) [package insert]","year":"2016"},{"key":"e_1_2_8_12_1","volume-title":"BAVENCIO (avelumab) [package insert]","year":"2017"},{"key":"e_1_2_8_13_1","volume-title":"LIBTAYO (cemiplimab\u2010rwlc) [package insert]","year":"2018"},{"key":"e_1_2_8_14_1","volume-title":"OPDIVO (nivolumab) [package insert]","year":"2014"},{"key":"e_1_2_8_15_1","volume-title":"YERVOY (ipilimumab) [package insert]","year":"2011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0474-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.03.001"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354449"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5023-8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-03-900928"},{"key":"e_1_2_8_22_1","first-page":"22","article-title":"BiTE: teaching antibodies to engage T\u2010cells for cancer therapy","volume":"11","author":"Baeuerle PA","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12393"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.651"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1396"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"e_1_2_8_29_1","volume-title":"BLINCYTO\u00ae (blinatumomab) Approved in Japan for the Treatment of Relapsed or Refractory B\u2010Cell Acute Lymphoblastic Leukemia. First Approved Oncology Treatment From Amgen Astellas Joint Venture","author":"Amgen Inc","year":"2018"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019034"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000564724.75061.cc"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24987"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24783"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0023-x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12105"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000169"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0014-3"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0423-1"},{"key":"e_1_2_8_46_1","volume-title":"Blincyto (Blinatumomab) [package insert]","author":"Amgen Inc","year":"2019"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0760-1"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000686"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123757"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020198"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547"},{"issue":"13","key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/1538-7445.AM2017-55","article-title":"Abstract 55: Generation of half\u2010life extended anti\u2010CD33 BiTE\u00ae antibody constructs compatible with once\u2010weekly dosing","volume":"77","author":"Arvedson TL","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_8_53_1","first-page":"2815","article-title":"Generation of a half\u2010life extended anti\u2010CD19 BiTE\u00ae antibody construct compatible with once\u2010weekly dosing for treatment of CD19\u2010positive malignancies [abstract]","volume":"130","author":"Lorenczewski G","year":"2017","journal-title":"Blood"},{"issue":"1","key":"e_1_2_8_54_1","first-page":"5389","article-title":"Generation of half\u2010life extended anti\u2010BCMA BiTE\u00ae antibody construct compatible with once\u2010weekly dosing for treatment of multiple myeloma (MM) [abstract]","volume":"130","author":"Goyos A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_55_1","unstructured":"Amgen Inc.Amgen Pipeline. Accessed April 30 2019.https:\/\/www.amgenpipeline.com\/pipeline\/"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"e_1_2_8_59_1","volume-title":"Anti\u2010BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma","author":"Lederman L","year":"2019"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1122780"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523548"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527044"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1452911"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0042"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.5034"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.124"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.301"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos218"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz219.1195"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13997"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8577"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1279-8"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1547"},{"key":"e_1_2_8_74_1","doi-asserted-by":"crossref","first-page":"LB\u2010299","DOI":"10.1158\/1538-7445.AM2018-LB-299","article-title":"Abstract LB\u2010299: Cynomolgus monkey plasma cell gene signature to quantify the in vivo activity of a half\u2010life extended anti\u2010BCMA BiTE\u00ae for the treatment of multiple myeloma","volume":"78","author":"Goyos A","year":"2018","journal-title":"Cancer Res"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32909","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32909","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32909","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:40:27Z","timestamp":1760305227000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":73,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,7,15]]}},"alternative-id":["10.1002\/cncr.32909"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32909","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"2019-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}